Earnings Feed
Start Free
Kiniksa Pharmaceuticals International, plc·4

Jun 2, 4:52 PM ET

Quart Barry D 4

Research Summary

AI-generated summary

Updated

Kiniksa (KNSA) Director Barry D. Quart Receives RSUs & Exercises Options

What Happened

  • Barry D. Quart, a director of Kiniksa Pharmaceuticals International, plc (KNSA), received equity awards and exercised an option on May 29, 2026. The filing shows grants of 12,158 RSUs and 2,026 RSUs (total 14,184 RSUs) that vested in full, and an exercise/conversion of 2,799 derivative shares (options). The filing also reports the disposition (surrender) of 2,799 shares on the same date. Prices for the grants and the reported dispositions are $0.00 in the filing (typical for RSU grants and net settlements).
  • This is primarily an award/vesting event (RSUs granted and vested). The option exercise followed by an equal-number disposition looks like a net settlement or surrender of shares (commonly used to cover taxes or exercise costs), not an open‑market sale for cash.

Key Details

  • Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (no late‑filing flag shown in the provided excerpt).
  • Grants: 12,158 RSUs (F3/F4) and 2,026 RSUs (F1/F3/F4) — total 14,184 RSUs; each RSU converts to one Class A Ordinary Share when paid.
  • Option exercise: 2,799 derivative shares exercised/converted (code M); 2,799 shares simultaneously disposed (reported at $0.00).
  • Prices/values: Grants reported at $0.00 (typical for RSU awards); no cash sales or market value reported in the excerpt.
  • Shares owned after the transactions: not provided in the supplied filing details — see the full SEC filing for current beneficial ownership amounts.
  • Relevant footnotes:
    • F1: Each RSU equals a contingent right to one Class A Ordinary Share.
    • F2: The option vests monthly starting May 29, 2026 (grant date).
    • F3/F4: The RSUs vested in their entirety on May 29, 2026 (vested in a single installment; no expiration).

Context

  • RSU grants and vesting are compensation events and do not necessarily signal buying or selling intent by the insider. The exercise plus immediate disposition of the same number of shares is often a net settlement or share surrender (commonly to cover taxes or exercise costs) rather than an open‑market sale. For complete details and any monetary amounts, consult the full Form 4 (Accession 0001384243-26-000012).